The 19th National Clinical Oncology Congress & Chinese Society of Clinical Oncology (CSCO) was held from September 21-25, 2016, in Xiamen, China. As the premier event of clinical oncology, the CSCO meeting attracted more than 20,000 domestic representatives and more than 150 enterprises and institutions and academic organizations related to oncology. Editors (Lisa Huang and Catherine Jin) of Hepatoma Research (HR) and Dandan Yu, the publication manager of OAE Publishing Inc., took part in the conference to promote the journal and improve communication around it in the international conference and learn the latest developments in clinical liver cancer.
The theme of the conference was "Fine Management, Precision Heal," and was held across 59 Chinese and 9 English sessions, and had more than 500 special reports and more than 1,200 articles. It especially held the Educational Session: Hepatobiliary & Pancreatic Cancer and hepatocellular carcinoma (HCC) Symposium, bringing together Prof. Shu-kui Qin (Bayi hospital of Nanjing, China) and Prof. Feng Shen (Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, China). Prof. Qin gave a lecture of "Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial." Prof. Shen reported on "The recent advances in the treatment of primary liver cancer of liver transplantation." Additionally, Prof. Jia Fan discussed "The recent advances in the treatment of primary liver cancer resection." By carefully listening to reports, our editors learned about new technology and progress in the field of liver cancer and communicated this with experts home and abroad. Prof David Carbone provided relevant suggestions and affirmed the development of HR.
From left to right: Lisa Huang, Dandan Yu, and Prof. Shu-kui Qin
From left to right: Catherine Jin, Prof. David Carbone, Dandan Yu, and Lisa Huang
As the honorary editor, Prof. Qin required that we pay attention to international liver cancer research, especially in the Asia Pacific region, track the current topics in a timely manner, implement rigorous peer review, and provide the best service to authors and readers. He also encouraged us to insist on publishing high-quality articles as the fundamental approach to developing and becoming a perfect open-access platform for liver cancer, and eventually become a top-class international academic journal in the field of hepatoma.
Finally, we would like to thank the experts' and professors' affirmation of HR and for supporting us and believing that we will constantly improve.